Results of Peripheral Blood Stem Cells According to Stimulatory Molecule,: Zarzio Versus Granocytes
NCT03367117 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70
Last updated 2017-12-08
Summary
Investigator therefore propose a retrospective mono-centric study, to compare the results obtained in patients with myeloma or lymphoma, mobilized with Zarzio® in order to obtain a graft, with the results obtained in our study. retrospective cohort of mobilization by Granocyte®.
Conditions
- Hematology, Graft, Mobilization
Sponsors & Collaborators
-
University Hospital, Brest
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-10-10
- Primary Completion
- 2017-01-23
- Completion
- 2017-01-23
More Related Trials
-
Non-interventional, Long-term Safety Data Collection of Zarzio® / Filgrastim HEXAL® in Stem Cell Donors
NCT01766934 ·Status: COMPLETED
-
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT01076270 ·Status: TERMINATED ·Phase: NA
-
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies
NCT01413568 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
NCT02639559 ·Status: COMPLETED ·Phase: PHASE2
-
Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma
NCT02221479 ·Status: COMPLETED ·Phase: PHASE2
-
HLA-mismatched Microtransplantation Without Immunosuppressive Treatment in Patients With Myeloid Hemopathies
NCT03232268 ·Status: COMPLETED ·Phase: PHASE1
-
PEG-rhG-CSF Compared With rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation
NCT05156554 ·Status: UNKNOWN ·Phase: NA
-
Auto Stem Cell Transplant for Lymphoma Patients
NCT03125642 ·Status: RECRUITING ·Phase: PHASE2
-
Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome
NCT00003961 ·Status: COMPLETED ·Phase: PHASE2
-
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
NCT03948529 ·Status: TERMINATED ·Phase: PHASE2
-
Palifermin for Patients Receiving Hematopoietic Stem Cell Transplantation
NCT02313792 ·Status: UNKNOWN ·Phase: PHASE3
-
G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome
NCT00228813 ·Status: TERMINATED ·Phase: NA
-
Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia
NCT00053157 ·Status: COMPLETED ·Phase: NA
-
Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases
NCT00438958 ·Status: COMPLETED ·Phase: PHASE3
-
Fludarabine, Busulfan, Antithymocyte Globulin, and Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma That Has Not Responded to Treatment
NCT00802568 ·Status: COMPLETED ·Phase: PHASE2
-
Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)
NCT00231309 ·Status: COMPLETED ·Phase: NA
-
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT02960646 ·Status: COMPLETED ·Phase: PHASE1
-
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
NCT01233921 ·Status: COMPLETED ·Phase: NA
-
Treatment of Refractory (Acute or Chronic) Graft-Versus-Host Disease by the Infusion of Expanded in-Vitro Allogenic Mesenchymal Stem Cell
NCT00447460 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant
NCT03821519 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Granulocyte Colony Stimulating Factor (G-CSF) After Salvage Chemotherapy in Refractory AML
NCT02427919 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts
NCT00396331 ·Status: COMPLETED ·Phase: PHASE2
-
US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia
NCT04103879 ·Status: COMPLETED ·Phase: PHASE2
-
Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders
NCT00740467 ·Status: UNKNOWN ·Phase: PHASE2
-
Allogeneic Hematopoietic Stem Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-thymocyte Globulin for Older Patients With Relapsed Lymphoid Malignancies
NCT01566656 ·Status: COMPLETED ·Phase: PHASE2